医学
肾病
胃肠病学
补体系统
肾功能
泌尿系统
肾小球肾炎
内科学
发病机制
肌酐
病理
免疫学
蛋白尿
替代补体途径
抗体
肾
内分泌学
糖尿病
作者
Hiroe Itami,Shigeo Hara,Ken‐ichi Samejima,Hideo Tsushima,Katsuhiko Morimoto,Keisuke Okamoto,Takaaki Kosugi,Takahiro Kawano,Kengo Fujiki,Hiromichi Kitada,Kinta Hatakeyama,Kazuhiko Tsuruya,Chiho Ohbayashi
出处
期刊:Virchows Archiv
[Springer Science+Business Media]
日期:2020-04-16
卷期号:477 (4): 565-572
被引量:32
标识
DOI:10.1007/s00428-020-02800-0
摘要
IgA nephropathy (IgAN) is common chronic glomerulonephritis with variable prognosis, ranging from minor urinary abnormalities to end-stage renal disease. The revised Oxford classification of IgAN explains that cellular/fibrocellular crescents are associated with poor renal prognosis, proposing an extension to the MEST-C score. C3 immunofluorescent staining follows a distribution similar to IgA staining. Therefore, complement activation was reported to play a pivotal role in IgAN pathogenesis. This study included 132 IgAN patients diagnosed by renal biopsies. The clinical parameters at the time of the biopsies were obtained from patient data records. We classified the patients into C ≥ 1 and C0 groups, and compared clinical, light microscopic, and immunofluorescent features. In the C ≥ 1 group, 2 (1.5%) and 31 (23.5%) patients were assigned to C2 and C1, respectively. The remaining 99 patients (75%) were classified as C0. The C ≥ 1 group had lower average age and rate of hypertension, and higher score of urinary occult blood and E score. The C ≥ 1 group had significantly higher average immunofluorescence scores for IgA, C5b-9, mannose-associated serine protease (MASP) 1/3, MASP2, properdin, factor B, and kappa. The steroid use rate was significantly higher in the C ≥ 1 group. During the follow-up period of 2.90 years on average, the rate of renal dysfunction was not significantly different between groups. Crescent formation in IgAN was associated with activation of the lectin and alternative pathways. The C ≥ 1 group had significantly increased use of steroids, which probably caused comparable renal function during the follow-up period.
科研通智能强力驱动
Strongly Powered by AbleSci AI